Pharmacotherapy for Uveitis: Current Management and Emerging Therapy

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2014 Oct 7

PMID 25284976

Citations 32

Authors

Robert J Barry

Quan Dong Nguyen

Richard W Lee

Philip I Murray

Alastair K Denniston

Affiliations

Soon will be listed here.

Abstract

Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.

Citing Articles

Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases.

Yavari N, Ghoraba H, Or C, Thng Z, Mohammadi S, Karaca I J Ophthalmic Inflamm Infect. 2024; 14(1):56.

PMID: 39448433 PMC: 11502637. DOI: 10.1186/s12348-024-00428-8.

Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.

Chauhan K, Tyagi M Front Ophthalmol (Lausanne). 2024; 4:1412930.

PMID: 39157460 PMC: 11327136. DOI: 10.3389/fopht.2024.1412930.

Healthcare professionals' views on the most important outcomes for non-infectious uveitis of the posterior segment: A qualitative study.

Tallouzi M, Moore D, Bucknall N, Murray P, Calvert M, Denniston A PLoS One. 2023; 18(11):e0294117.

PMID: 37976313 PMC: 10655978. DOI: 10.1371/journal.pone.0294117.

Effects of Subcutaneous Methotrexate in Patients with Refractory Uveitis and Chorioretinitis.

Lee S, Choo H, Kwon O, You Y Korean J Ophthalmol. 2023; 37(6):446-452.

PMID: 37899284 PMC: 10721398. DOI: 10.3341/kjo.2023.0073.

Extracellular vesicles as a new horizon in the diagnosis and treatment of inflammatory eye diseases: A narrative review of the literature.

Habibi A, Zarei-Behjani Z, Falamarzi K, Malekpour M, Ebrahimi F, Soleimani M Front Immunol. 2023; 14:1097456.

PMID: 36969177 PMC: 10033955. DOI: 10.3389/fimmu.2023.1097456.

References

Tian L, Yang P, Lei B, Shao J, Wang C, Xiang Q . AAV2-mediated subretinal gene transfer of hIFN-α attenuates experimental autoimmune uveoretinitis in mice. PLoS One. 2011; 6(5):e19542. PMC: 3096632. DOI: 10.1371/journal.pone.0019542. View

Lubberts E, Koenders M, van den Berg W . The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005; 7(1):29-37. PMC: 1064899. DOI: 10.1186/ar1478. View

Mandelcorn E . Infectious causes of posterior uveitis. Can J Ophthalmol. 2013; 48(1):31-9. DOI: 10.1016/j.jcjo.2012.11.013. View

Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B . Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001; 44(6):1411-5. DOI: 10.1002/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O. View

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

Wakabayashi T, Morimura Y, Miyamoto Y, Okada A . Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm. 2004; 11(4):277-86. DOI: 10.1076/ocii.11.4.277.18260. View

He Y, Jia S, Zhang W, Shi J . New options for uveitis treatment. Int J Ophthalmol. 2013; 6(5):702-7. PMC: 3808925. DOI: 10.3980/j.issn.2222-3959.2013.05.29. View

Sen H, Levy-Clarke G, Faia L, Li Z, Yeh S, Barron K . High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009; 148(5):696-703.e1. PMC: 2922905. DOI: 10.1016/j.ajo.2009.06.003. View

Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V . Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2013; 22(2):90-5. DOI: 10.3109/09273948.2013.844265. View

10.

Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster C . Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 2002; 109(1):137-42. DOI: 10.1016/s0161-6420(01)00864-8. View

11.

Becker B, Mills D . ELEVATED INTRAOCULAR PRESSURE FOLLOWING CORTICOSTEROID EYE DROPS. JAMA. 1963; 185:884-6. DOI: 10.1001/jama.1963.03060110088027. View

12.

Jabs D, Nussenblatt R, Rosenbaum J . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140(3):509-16. PMC: 8935739. DOI: 10.1016/j.ajo.2005.03.057. View

13.

Artornsombudh P, Gevorgyan O, Payal A, Siddique S, Foster C . Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology. 2012; 120(3):588-592. DOI: 10.1016/j.ophtha.2012.05.048. View

14.

Nguyen Q, Ibrahim M, Watters A, Bittencourt M, Yohannan J, Sepah Y . Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 2013; 3(1):32. PMC: 3610181. DOI: 10.1186/1869-5760-3-32. View

15.

Hemady R, Baer J, Foster C . Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin. 1992; 32(1):241-52. DOI: 10.1097/00004397-199203210-00018. View

16.

Zarbin M, Jampol L, Jager R, Reder A, Francis G, Collins W . Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013; 120(7):1432-9. DOI: 10.1016/j.ophtha.2012.12.040. View

17.

Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P . Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997; 6(3):315-25. DOI: 10.1016/s1074-7613(00)80334-9. View

18.

Wooley P, Dutcher J, Widmer M, Gillis S . Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol. 1993; 151(11):6602-7. View

19.

Amadi-Obi A, Yu C, Liu X, Mahdi R, Clarke G, Nussenblatt R . TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007; 13(6):711-8. DOI: 10.1038/nm1585. View

20.

Miserocchi E, Pontikaki I, Modorati G, Bandello F, Meroni P, Gerloni V . Rituximab for uveitis. Ophthalmology. 2011; 118(1):223-4. DOI: 10.1016/j.ophtha.2010.07.031. View